Easing the burden of premenstrual dysphoric disorder

,; ,; ,; ,; ,

Applied Evidence

Easing the burden of premenstrual dysphoric disorder

J Fam Pract. 2013 January;62(1):E1-E7

PDF Download

References

1. Mishell DR, Jr. Premenstrual disorders: epidemiology and disease burden. Am J Manag Care. 2005;11(suppl 16):S473-S479.

2. Kaur G, Gonsalves L, Thacker HL. Premenstrual dysphoric disorder: a review for the treating practitioner. Cleve Clin J Med. 2004;71:303-305,312–313, 317–318.

3. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders DSM-IV-TR. 4th ed. text revision. Washington, DC: American Psychiatric Association; 2000.

4. Kim DR, Gyulai L, Freeman EW, et al. Premenstrual dysphoric disorder and psychiatric co-morbidity. Arch Womens Ment Health. 2004;7:37-47.

5. Ling FW. Recognizing and treating premenstrual dysphoric disorder in the obstetric, gynecologic, and primary care practices. J Clin Psychiatry. 2000;61(suppl 12):S9-S16.

6. Steiner M, Pearlstein T. Premenstrual dysphoria and the serotonin system: pathophysiology and treatment. J Clin Psychiatry. 2000;61(suppl 12):S17-S21.

7. Freeman EW, Sondheimer SJ. Premenstrual dysphoric disorder: recognition and treatment. Prim Care Companion J Clin Psychiatry. 2003;5:30-39.

8. Silber TJ, Valadez-Meltzer A. Premenstrual dysphoric disorder in adolescents: case reports of treatment with fluoxetine and review of the literature. J Adolesc Health. 2005;37:518-525.

9. Pearlstein TB, Bellew KM, Endicott J, et al. Paroxetine controlled release for premenstrual dysphoric disorder: remission analysis following a randomized, double-blind, placebo-controlled trial. Prim Care Companion J Clin Psychiatry. 2005;7:53-60.

10. Halbreich U, Petty F, Yonkers K, et al. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with premenstrual dysphoric disorder. Am J Psychiatry. 1996;153:718-720.

11. Jarvis CI, Lynch AM, Morin AK. Management strategies for premenstrual syndrome/premenstrual dysphoric disorder. Ann Pharmacother. 2008;42:967-978.

12. Kaura V, Ingram CD, Gartside SE, et al. The progesterone metabolite allopregnanolone potentiates GABA(A) receptor-mediated inhibition of 5-HT neuronal activity. Eur Neuropsychopharmacol. 2007;17:108-115.

13. Girdler SS, Straneva PA, Light KC, et al. Allopregnanolone levels and reactivity to mental stress in premenstrual dysphoric disorder. Biol Psychiatry. 2001;49:788-797.

14. Klatzkin RR, Lindgren ME, Forneris CA, et al. Histories of major depression and premenstrual dysphoric disorder: Evidence for phenotypic differences. Biol Psychol. 2010;84:235-247.

15. Girdler SS, Klatzkin R. Neurosteroids in the context of stress: implications for depressive disorders. Pharmacol Ther. 2007;116:125-139.

16. Perkonigg A, Yonkers KA, Pfister H, et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry. 2004;65:1314-1322.

17. Tschudin S, Bertea PC, Zemp E. Prevalence and predictors of premenstrual syndrome and premenstrual dysphoric disorder in a population-based sample. Arch Womens Ment Health. 2010;13:485-494.

18. Girdler SS, Leserman J, Bunevicius R, et al. Persistent alterations in biological profiles in women with abuse histories: influence of premenstrual dysphoric disorder. Health Psychol. 2007;26:201-213.

19. Girdler SS, Sherwood A, Hinderliter AL, et al. Biological correlates of abuse in women with premenstrual dysphoric disorder and healthy controls. Psychosom Med. 2003;65:849-856.

20. Miyaoka Y, Akimoto Y, Ueda K, et al. Fulfillment of the premenstrual dysphoric disorder criteria confirmed using a self-rating questionnaire among Japanese women with depressive disorders. Biopsychosoc Med. 2011;5:5.-

21. Rapkin A, Winer S. Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness. Expert Rev Pharmacoecon Outcomes Res. 2009;9:157-170.

22. Cunningham J, Yonkers KA, O’Brien S, et al. Update on research and treatment of premenstrual dysphoric disorder. Harv Rev Psychiatry. 2009;17:120-137.

23. Dickerson LM, Hunter MH. Premenstrual syndrome. Am Fam Physician. 2003;67:1743-1752.

24. Steiner M, Macdougall M, Brown E. The premenstrual symptoms screening tool (PSST) for clinicians. Arch Womens Ment Health. 2003;6:203-209.

25. Halbreich U, O’Brien PM, Eriksson E, et al. Are there differential symptom profiles that improve in response to different pharmacological treatments of premenstrual syndrome/premenstrual dysphoric disorder? CNS Drugs. 2006;20:523-547.

26. Bianchi-Demicheli F. Premenstrual dysphoric disorder: diagnosis and therapeutic strategy. Rev Med Suisse. 2006;2:393-394,397–399.

27. Htay TT, Carrick J, Papiaca R. Premenstrual dysphoric disorder 2009. Available at: http://emedicine.medscape.com/article/293257-clinical. Accessed May 25, 2011.

28. Halbreich U. Selective serotonin reuptake inhibitors and initial oral contraceptives for the treatment of PMDD: effective but not enough. CNS Spectr. 2008;13:566-572.

29. Brown J, Marjoribanks J, Wyatt K. Selective serotonin reuptake inhibitors for premenstrual syndrome. Cochrane Database Syst Rev. 2009;(2):CD001396.-

30. Freeman EW. Effects of antidepressants on quality of life in women with premenstrual dysphoric disorder. Pharmacoeconomics. 2005;23:433-444.

31. Landen M, Nissbrandt H, Allgulander C, et al. Placebo-controlled trial comparing intermittent and continuous paroxetine in premenstrual dysphoric disorder. Neuropsychopharmacology. 2007;32:153-161.

32. Freeman EW, Rickels K, Yonkers KA, et al. Venlafaxine in the treatment of premenstrual dysphoric disorder. Obstet Gynecol. 2001;98:737-744.

33. Kroll R, Rapkin AJ. Treatment of premenstrual disorders. J Reprod Med. 2006;51(suppl 4):S359-S370.

34. Eriksson E, Ekman A, Sinclair S, et al. Escitalopram administered in the luteal phase exerts a marked and dose-dependent effect in premenstrual dysphoric disorder. J Clin Psychopharmacol. 2008;28:195-202.

35. Halbreich U. The pathophysiologic background for current treatments of premenstrual syndromes. Curr Psychiatry Rep. 2002;4:429-434.

36. Wyatt KM, Dimmock PW, Frischer M, et al. Prescribing patterns in premenstrual syndrome. BMC Womens Health. 2002;2:4.-

37. Rapkin AJ. YAZ in the treatment of premenstrual dysphoric disorder. J Reprod Med. 2008;53(suppl 9):S729-S741.

38. Elliott H. Premenstrual dysphoric disorder. A guide for the treating clinician. NC Med J. 2002;63:72-75.

39. Dante G, Facchinetti F. Herbal treatments for alleviating premenstrual symptoms: a systematic review. J Psychosom Obstet Gynaecol. 2011;32:42-51.

40. Whelan AM, Jurgens TM, Naylor H. Herbs, vitamins and minerals in the treatment of premenstrual syndrome: a systematic review. Can J Clin Pharmacol. 2009;16:e407-e429.

41. Pearlstein T, Steiner M. Non-antidepressant treatment of premenstrual syndrome. J Clin Psychiatry. 2000;61(suppl 12):22-27.

42. Girman A, Lee R, Kligler B. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol. 2003;188(suppl 5):S56-S65.

43. Wyatt KM, Dimmock PW, Jones PW, et al. Efficacy of vitamin B₆ in the treatment of premenstrual syndrome: systematic review. BMJ. 1999;318:1375-1381.

44. Freeman EW. Therapeutic management of premenstrual syndrome. Expert Opin Pharmacother. 2010;11:2879-2889.

45. NIH Consensus Conference. Acupuncture. JAMA. 1998;280:1518-1524.

46. Taguchi R, Yoshimoto S, Imai K, et al. Acupuncture for premenstrual dysphoric disorder. Arch Gynecol Obstet. 2009;280:877-881.